-
公开(公告)号：EP2399993B1
公开(公告)日：2017-09-20
申请号：EP10743584.4
申请日：2010-02-19
CPC分类号： B82Y5/00 , A61K47/6898 , C07K14/36 , C07K16/14 , C07K2317/56 , C07K2317/622 , C07K2317/92
-
公开(公告)号：EP1947460B1
公开(公告)日：2012-05-30
申请号：EP06832519.0
申请日：2006-11-10
发明人： KODAMA, Tatsuhiko , HAMAKUBO, Takao , MAEMURA, Koji, The University of Tokyo , SUGIYAMA, Akira , IWANARI, Hiroko , KOHNO, Isao , ITO, Yukio
IPC分类号： G01N33/68 , G01N33/53 , G01N33/577 , C07K16/18 , C12N15/09
CPC分类号： C07K16/18 , G01N33/577 , G01N33/6893 , G01N2800/324 , Y10S435/81
摘要： A method of judging vascular disorders as a risk factor of myocardial infarction, angiopathic dementia, etc. at an early date, namely, mild vascular disorders. There is provided a method of judging the degree of mild vascular disorders, characterized in that the level of PTX3 in a test sample is measured with the use of anti-PTX3 monoclonal antibody.
-
3.发明公开METHOD OF MEASURING PTX3 WITH HIGH SENSITIVITY 有权VERFAHREN ZUR PTX3-MESSUNG MIT HOHER EMPFINDLICHKEIT
公开(公告)号：EP1947460A1
公开(公告)日：2008-07-23
申请号：EP06832519.0
申请日：2006-11-10
发明人： KODAMA, Tatsuhiko , HAMAKUBO, Takao , MAEMURA, Koji, The University of Tokyo , SUGIYAMA, Akira , IWANARI, Hiroko , KOHNO, Isao , ITO, Yukio
IPC分类号： G01N33/68 , G01N33/53 , G01N33/577 , C07K16/18 , C12N15/09
CPC分类号： C07K16/18 , G01N33/577 , G01N33/6893 , G01N2800/324 , Y10S435/81
摘要： To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.
摘要翻译： 提供一种在早期阶段（即轻度血管病变）确定血管病变的方法，血管病变是心肌梗死，血管性痴呆等的危险因素。 本发明提供了确定轻度血管病变的严重性的方法，包括通过使用抗PTX3单克隆抗体测定测定样品中的PTX3水平。
-
公开(公告)号：EP2399993A9
公开(公告)日：2012-07-18
申请号：EP10743584.4
申请日：2010-02-19
IPC分类号： C12N15/09 , A61K31/4188 , A61K38/00 , A61K39/395 , A61P37/06 , C07K14/195 , C07K16/00 , C07K19/00 , G01N33/53
CPC分类号： B82Y5/00 , A61K47/6898 , C07K14/36 , C07K16/14 , C07K2317/56 , C07K2317/622 , C07K2317/92
摘要： It is an object of the present invention to provide a mutant streptavidin wherein the immunogenicity (antigenicity) in mammals of a streptavidin is reduced. The present invention provides a mutant streptavidin, which comprises an amino acid sequence in which (a) the arginine residue at position 72 is substituted with another amino acid residue, and (b) any one or more of the tyrosine residue at position 10, the tyrosine residue at position 71, the glutamic acid residue at position 89, the arginine residue at position 91, and the glutamic acid residue at position 104 are substituted with other amino acid residues, with respect to the amino acid sequence of a core streptavidin as shown in SEQ ID NO: 2, and which has decreased immunogenicity as compared with that of a wild-type streptavidin.
-
5.发明公开
公开(公告)号：EP2399993A1
公开(公告)日：2011-12-28
申请号：EP10743584.4
申请日：2010-02-19
IPC分类号： C12N15/09 , A61K31/4188 , A61K38/00 , A61K39/395 , A61P37/06 , C07K14/195 , C07K16/00 , C07K19/00 , G01N33/53
CPC分类号： B82Y5/00 , A61K47/6898 , C07K14/36 , C07K16/14 , C07K2317/56 , C07K2317/622 , C07K2317/92
摘要： It is an object of the present invention to provide a mutant streptavidin wherein the immunogenicity (antigenicity) in mammals of a streptavidin is reduced. The present invention provides a mutant streptavidin, which comprises an amino acid sequence in which (a) the arginine residue at position 72 is substituted with another amino acid residue, and (b) any one or more of the tyrosine residue at position 10, the tyrosine residue at position 71, the glutamic acid residue at position 89, the arginine residue at position 91, and the glutamic acid residue at position 104 are substituted with other amino acid residues, with respect to the amino acid sequence of a core streptavidin as shown in SEQ ID NO: 2, and which has decreased immunogenicity as compared with that of a wild-type streptavidin.
摘要翻译： 本发明的一个目的是提供一种突变链霉抗生物素蛋白，其中链霉抗生物素蛋白的哺乳动物中的免疫原性（抗原性）降低。 本发明提供一种突变链霉抗生物素蛋白，其包含其中（a）第72位的精氨酸残基被另一个氨基酸残基取代的氨基酸序列，和（b）第10位的任何一个或多个酪氨酸残基， 对于核心链霉抗生物素蛋白的氨基酸序列，如图所示，第71位的酪氨酸残基，89位的谷氨酸残基，91位的精氨酸残基和104位的谷氨酸残基被其他氨基酸残基取代 与野生型链霉抗生物素蛋白相比具有降低的免疫原性。
-
公开(公告)号：EP4141017A1
公开(公告)日：2023-03-01
申请号：EP21792412.5
申请日：2021-04-23
发明人： KANAI, Motomu , YAMATSUGU, Kenzo , TATSUMI, Toshifumi , KODAMA, Tatsuhiko , SUGIYAMA, Akira , TSUKAGOSHI, Masanobu , TOKUYAMA, Hidetoshi , SAKATA, Juri
摘要： It is an object of the present invention to provide a conjugate of a duocarmycin derivative and a biotin-modified dimer, which is useful for pretargeting methods. According to the present invention, a compound represented by the following formula (1) or formula (2) is provided:
wherein R 1 and R 2 each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group; one of R 3 , R 4 , and R 5 represents -O-L 7 -(Xaa) m -L 6 -N 3 , and the remaining two each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group; X represents a reactive group; L 6 and L 7 each independently represent a divalent linking group; Xaa represents an amino acid residue; m represents an integer of 2 to 10; and Me represents a methyl group.-
公开(公告)号：EP4382609A1
公开(公告)日：2024-06-12
申请号：EP22849576.8
申请日：2022-07-28
发明人： TANAKA, Toshiya , YAMASHITA, Takefumi , KODAMA, Tatsuhiko , KANAI, Motomu , YAMATSUGU, Kenzo , TATSUMI, Toshifumi , TAKAHASHI, Kazuki , SUGIYAMA, Akira , TSUKAGOSHI, Masanobu , CHANSLER, Michael , NAKAI, Masanori
IPC分类号： C12N15/62 , A61K31/409 , A61K38/16 , A61K47/66 , A61K49/00 , A61P35/00 , C07K14/195 , C07K16/30 , C07K19/00 , C12P21/02
CPC分类号： A61K31/409 , A61K38/16 , A61K47/66 , A61K49/00 , A61P35/00 , C07K14/195 , C07K16/30 , C07K19/00 , C12N15/62 , C12P21/02
摘要： It is an object of the present invention to provide a fusion protein of a molecule that recognizes cancer cells or the like and a mutant streptavidin, wherein the fusion protein is for use in the treatment or diagnosis of a cancer. According to the present invention, provided is A fusion protein, wherein an antigen-binding molecule having a molecular weight of 20,000 or less is bound, via a linker sequence, to the N-terminal side and/or C-terminal side of mutant streptavidin which comprises an amino acid sequence having the following mutations (1) to (6) with respect to the amino acid sequence of a core streptavidin as shown in SEQ ID NO: 17 provided that the C-terminal amino acid sequence consisting of Pro-Ser-Ala-Ala-Ser may be partially or entirely deleted, and has a decreased immunogenicity as compared with that of a wild-type streptavidin:
(1) a mutation in which the tyrosine residue at position 10 is substituted with serine or threonine;
(2) a mutation in which the tyrosine residue at position 71 is substituted with alanine or serine;
(3) a mutation in which the arginine residue at position 72 is substituted with lysine;
(4) a mutation in which the glutamic acid residue at position 89 is substituted with aspartic acid;
(5) a mutation in which the arginine residue at position 91 is substituted with lysine; and
(6) a mutation in which the glutamic acid residue at position 104 is substituted with glutamine or asparagine.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.015 秒)
